The maintenance of a 'Sector Perform' rating suggests that RBC Capital does not foresee significant changes in Neurocrine Biosciences' stock performance relative to the sector. However, the reduction in the price target could imply a slightly more cautious outlook on the company's valuation, potentially leading to a neutral short-term impact on the stock price.